NCI-H226 Xenograft Model Service for NSCLC

The NCI-H226 xenograft model is a well-established preclinical platform for evaluating therapeutic strategies against lung squamous cell carcinoma (LUSC), a major histological subtype of non-small cell lung cancer (NSCLC) characterized by distinct molecular drivers including TP53 mutation, CDKN2A loss, and MET amplification. Alfa Cytology offers a comprehensive NCI-H226 xenograft model service designed to accelerate your oncology drug discovery pipeline, providing robust in vivo data from tumor establishment through endpoint analysis with rigorous quality control and regulatory-compliant reporting.

Overview of NCI-H226 Xenograft Model for NSCLC

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, with lung squamous cell carcinoma (LUSC) representing roughly 25–30% of NSCLC diagnoses. LUSC is strongly associated with a history of smoking and typically arises from the central airways and bronchi, exhibiting distinct molecular profiles compared to lung adenocarcinoma. The NCI-H226 cell line, originally established in 1980 from the pleural effusion of a male patient with squamous cell carcinoma, is a well-characterized model of LUSC that faithfully recapitulates the histopathological and molecular features of this disease subtype. Genomically, NCI-H226 harbors TP53 mutations and homozygous deletion of the CDKN2A locus, together with MET amplification and PTEN alterations—genomic hallmarks frequently observed in LUSC. These molecular characteristics make NCI-H226 an invaluable preclinical tool for studying squamous lung cancer biology and evaluating novel therapeutic interventions, including chemotherapy, targeted therapy, and immunotherapy approaches.

Fig 1. The dosing schedule for the combination study in the NCI-H226 s.c. xenograft model. (Kaneda, Ayumi, et al., 2020)

Cell line-derived xenograft (CDX) models utilizing NCI-H226 cells provide a reproducible and physiologically relevant preclinical system for assessing tumor growth kinetics, drug efficacy, resistance mechanisms, pharmacokinetics, and biomarker responses. When implanted into immunodeficient mice, NCI-H226 cells reliably form tumors with take rates of 50–100%, recapitulating key histopathological features of human LUSC, including epithelial morphology, keratinization, and squamous marker expression. Notably, NCI-H226 has been extensively utilized in studies evaluating the efficacy of chemotherapeutic agents such as paclitaxel and cisplatin, multi-targeted receptor tyrosine kinase inhibitors such as sunitinib, and immunotherapy strategies targeting the PD-1/PD-L1 axis. These models serve as a critical bridge between in vitro screening and clinical translation, enabling researchers to generate high-confidence efficacy data for LUSC-directed agents prior to advancing compounds into more complex development stages.

Cell Line Information: NCI-H226

The NCI-H226 cell line is a well-characterized human lung squamous cell carcinoma cell line that serves as a robust foundation for preclinical xenograft studies. Below is a comprehensive summary of its biological and culture characteristics:

Our Services

At Alfa Cytology, we leverage our extensive expertise in preclinical oncology model development to deliver validated NCI-H226 xenograft studies with rapid turnaround times and comprehensive data packages. Our integrated service platform spans from tumor establishment and in-life monitoring through histopathological and molecular endpoint analysis, ensuring that your LUSC-directed compound receives rigorous, publication-quality evaluation in a clinically relevant NSCLC setting.

Workflow of NCI-H226 Xenograft Model Construction

The construction of a reliable NCI-H226 xenograft model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth, consistent pharmacological responses, and regulatory-compliant data generation. Each study is initiated with thorough cell line authentication and host animal health screening, followed by systematic tumor implantation, monitoring, and endpoint analysis.

1. Cell Line Preparation and Quality Control: NCI-H226 cells are recovered from cryopreserved stocks and expanded under standardized culture conditions (RPMI 1640 + 10% FBS, 37°C, 5% CO₂). Prior to inoculation, cells undergo mycoplasma testing, STR authentication, and viability assessment to confirm identity and ensure optimal engraftment potential.
2. Host Mouse Selection and Acclimatization: Immunodeficient mouse strains—most commonly athymic nude (nu/nu), NOD-SCID, or NSG (NOD-scid IL2Rγnull) mice—are selected based on study objectives and immune requirements. Animals are acclimatized for a minimum of 5–7 days under controlled environmental conditions with health monitoring and body weight baseline recording.
3. Tumor Cell Inoculation: Log-phase NCI-H226 cells are harvested, washed, and resuspended in phosphate-buffered saline (PBS) or PBS/Matrigel mixture (typically 1:1 v/v). For subcutaneous models, 8 × 10⁶ cells in a volume of 100–200 µL are injected into the right flank. Orthotopic models involve intrathoracic injection to recapitulate the native tumor microenvironment and metastatic behavior.
4. Tumor Growth Monitoring and Randomization: Tumor development is monitored by caliper measurement twice weekly, with tumor volume calculated using the modified ellipsoid formula (V = 0.5 × length × width²). Mice are randomized into treatment groups when tumors reach a palpable volume of 100–200 mm³, ensuring balanced baseline tumor sizes across cohorts. Body weight and clinical signs are recorded concurrently.
5. Treatment Administration and In-Life Assessment: Test articles are administered according to the predefined dosing regimen (route, frequency, and duration). Tumor volume and body weight are measured at regular intervals throughout the treatment period. Tumor growth inhibition (TGI), tumor growth delay (TGD), and partial or complete response rates are calculated relative to vehicle-treated controls.
6. Endpoint Analysis and Data Reporting: At study termination, tumors are excised, weighed, and processed for downstream analyses. Standard endpoints include hematoxylin and eosin (H&E) histopathology, immunohistochemistry (IHC) for proliferation (Ki-67) and apoptosis (cleaved caspase-3) markers, squamous differentiation markers, MET pathway analysis, pharmacokinetic/pharmacodynamic (PK/PD) assessment, and biomarker profiling. A comprehensive study report with statistical analysis is delivered to the client.

Fig 2. NCI-H226 xenograft model construction workflow.

Case Study-NCI-H226 Xenograft Model Development

In a representative preclinical study, NCI-H226 cells were successfully engrafted into immunodeficient mice to evaluate the efficacy of a novel therapeutic candidate targeting lung squamous cell carcinoma. Following subcutaneous inoculation, tumors established consistently with a take rate exceeding 50%, reaching the target volume range within 4–8 weeks. Treatment cohorts received the investigational compound via oral gavage or intraperitoneal injection on a defined schedule, while vehicle controls received the formulation buffer. Tumor growth was monitored biweekly via caliper measurement, and body weights were recorded to assess treatment tolerability. At study endpoint, excised tumors were subjected to comprehensive histopathological and molecular characterization, revealing dose-dependent reductions in tumor burden, decreased Ki-67 proliferation indices, and elevated apoptotic markers. Pharmacokinetic sampling confirmed adequate systemic exposure, and the overall data package supported the compound's advancement into subsequent preclinical development stages. These findings demonstrate the utility of the NCI-H226 xenograft model as a robust platform for generating translational efficacy data in LUSC.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor, operational efficiency, and client-centric flexibility to deliver preclinical xenograft studies that meet the highest standards of the pharmaceutical and biotechnology industries. Our NCI-H226 NSCLC xenograft service is designed to accelerate your drug discovery timeline while ensuring data integrity and regulatory readiness.

• Expertise in LUSC models: Our scientific team has deep experience with squamous cell carcinoma biology and understands the nuances of modeling this histologically distinct NSCLC subtype, including TP53-driven tumor progression, CDKN2A loss, and MET amplification.
• Validated, authenticated cell lines: All NCI-H226 stocks are STR-authenticated, mycoplasma-negative, and maintained under rigorous quality control to ensure batch-to-batch consistency and reliable tumor engraftment.
• Flexible study design: We accommodate diverse dosing regimens, combination therapy protocols, biomarker-driven endpoints, and custom analytical requirements tailored to your compound's mechanism of action and development stage.
• Comprehensive endpoint portfolio: From standard tumor growth inhibition and histopathology to advanced molecular profiling, PK/PD integration, and biomarker validation, we provide a full spectrum of analytical capabilities.
• Regulatory-compliant operations: Our vivarium and laboratories operate under IACUC-approved protocols with adherence to GLP-like standards, ensuring data packages suitable for IND-enabling and regulatory submissions.
• Rapid study initiation and reporting: Typical NCI-H226 xenograft studies can be initiated within 2–4 weeks of contract execution, with comprehensive draft reports delivered promptly after study completion.

Contact Us

Ready to advance your lung squamous cell carcinoma therapeutic program with a validated NCI-H226 xenograft model? Contact us today to discuss your study requirements, receive a customized project proposal, and learn how Alfa Cytology can accelerate your preclinical oncology research. Our team of experienced scientists is standing by to design a study protocol that aligns with your discovery objectives and delivers actionable, high-quality data.

For research use only. Not intended for any clinical use.